RC
DGX icon

RegentAtlantic Capital’s Quest Diagnostics DGX Stock Holding History

RegentAtlantic Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$924K Buy
7,535
+3
+0% +$395 0.03% 326
2022
Q2 		$1M Sell
7,532
-282
-4% -$38.4K 0.03% 319
2022
Q1 		$1.07M Buy
7,814
+251
+3% +$35K 0.03% 309
2021
Q4 		$1.31M Sell
7,563
-25
-0.3% -$3.8K 0.04% 276
2021
Q3 		$1.1M Buy
7,588
+110
+1% +$16.1K 0.03% 287
2021
Q2 		$987K Buy
7,478
+99
+1% +$13K 0.03% 298
2021
Q1 		$947K Sell
7,379
-1,107
-13% -$136K 0.03% 287
2020
Q4 		$1.01M Buy
8,486
+136
+2% +$16.6K 0.04% 242
2020
Q3 		$956K Buy
8,350
+250
+3% +$29.5K 0.04% 234
2020
Q2 		$923K Buy
8,100
+417
+5% +$44.2K 0.05% 234
2020
Q1 		$617K Buy
7,683
+15
+0.2% +$1.55K 0.05% 250
2019
Q4 		$819K Sell
7,668
-497
-6% -$51.8K 0.05% 259
2019
Q3 		$874K Sell
8,165
-104
-1% -$10.7K 0.06% 245
2019
Q2 		$842K Sell
8,269
-98
-1% -$9.42K 0.06% 245
2019
Q1 		$752K Sell
8,367
-49
-0.6% -$4.25K 0.05% 250
2018
Q4 		$701K Buy
8,416
+51
+0.6% +$4.78K 0.06% 243
2018
Q3 		$903K Sell
8,365
-79
-0.9% -$8.66K 0.07% 237
2018
Q2 		$928K Sell
8,444
-130
-2% -$13.5K 0.08% 225
2018
Q1 		$860K Sell
8,574
-260
-3% -$26.6K 0.07% 225
2017
Q4 		$870K Sell
8,834
-261
-3% -$24.7K 0.07% 228
2017
Q3 		$852K Sell
9,095
-162
-2% -$17.2K 0.07% 223
2017
Q2 		$1.03M Buy
9,257
+56
+0.6% +$5.92K 0.09% 204
2017
Q1 		$903K Sell
9,201
-815
-8% -$77.7K 0.08% 212
2016
Q4 		$921K Sell
10,016
-1,905
-16% -$164K 0.09% 209
2016
Q3 		$1.01M Buy
11,921
+1,525
+15% +$128K 0.1% 188
2016
Q2 		$846K Buy
10,396
+2,093
+25% +$159K 0.08% 208
2016
Q1 		$593K Buy
8,303
+3,067
+59% +$206K 0.07% 227
2015
Q4 		$372K Buy
5,236
+1,880
+56% +$126K 0.04% 286
2015
Q3 		$206K Buy
+3,356
New +$235K 0.02% 353
2015
Q1 		– Sell
-1,762
Closed -$118K – 496
2014
Q4 		$118K Buy
+1,762
New +$111K 0.01% 436

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RegentAtlantic Capital's DGX Position: Q3 2022 in Review

RegentAtlantic Capital increased its Quest Diagnostics (DGX) stake by 0.04% in Q3 2022, buying an estimated $395 and bringing the position to 7,535 shares worth $924K. The position accounts for 0.03% of the portfolio, ranked #326.

RegentAtlantic Capital first reported a position in DGX in Q4 2014 and has held it in 30 quarters since. The position peaked at $1.31M in Q4 2021. 808 funds tracked by Wall St. Rank hold DGX as of Q3 2022.

  • RegentAtlantic Capital held 7,535 shares of Quest Diagnostics worth $924K as of Q3 2022.
  • RegentAtlantic Capital bought 3 Quest Diagnostics shares in Q3 2022, an estimated $395.
  • Quest Diagnostics made up 0.03% of RegentAtlantic Capital's portfolio in Q3 2022, its #326 holding.
  • RegentAtlantic Capital first reported a position in Quest Diagnostics in Q4 2014 and has held it in 30 quarters since.
  • RegentAtlantic Capital's Quest Diagnostics position peaked at $1.31M in Q4 2021.
  • 808 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.